Clinical trial
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL…
NCT00278889 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00278889 |
|---|---|
| Title | Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) |
| Official title | A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer |
| Acronym | HORIZON I |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | AZD2171, 5-fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab |
| Enrollment | 215 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Oct 1, 2009 |
| First posted | Jan 19, 2006 |
| Last update posted | Oct 24, 2012 |
| Countries | Austria, Belgium, Canada, Czechia, France, Germany, Italy, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: